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ABSTRACT
Breast cancer encompasses a collection of different diseases
characterizedbydifferentbiological andpathological features,
clinicalpresentation, response to treatments, clinicalbehavior,
and outcome. On the basis of cell morphology, growth, and
architecture patterns, breast cancer can be classified in up to
21 distinct histological types. Breast cancer special types,
including the classic lobular invasive carcinoma, represent
25% of all breast cancers. The histological diversity of breast
carcinomas has relevant prognostic implications. Indeed,
the rare breast cancer group includes subtypes with very
different prognoses, ranging from the tubular carcinoma,
associated with an indolent clinical course, to metaplastic
cancer, whose outcome is generally unfavorable. New
approaches based on gene expression profiling allow the
identification of molecularly defined breast cancer classes,
with distinct biological features and clinical behavior. In
clinical practice, immunohistochemical classification based
on the expression of human epidermal growth factor
receptor 2 and Ki67 is applied as a surrogate of the intrinsic
molecular subtypes. However, the identification of intrinsic
molecular subtypes were almost completely limited to the
study of ductal invasive breast cancer.Moreover, some good-
prognosis triple-negative histotypes, on the basis of gene
expression profiling, can be classified among the poor-
prognosis group. Therefore, histopathological classification
remains a crucial component of breast cancer diagnosis.
Special histologies can be very rare, and the majority of
information on outcome and treatments derives from small
series and case reports. As a consequence, clear recommen-
dations about clinical management are still lacking. In this
review, we summarize current knowledge about rare breast
cancer histologies. The Oncologist 2014;19:805–813
Implications for Practice: Breast cancer special histologies encompass a panel of various entities with peculiar clinical behaviors.
The rarityof suchhistotypeshas jeopardizedanextensiveclinical evaluation.A reviewofcurrentavailabledatamayhelpphysicians
in their clinical practice; however, the development of clear clinical recommendations is not possible. Decisions on the
management of patientswith rare breast cancer histologies should derive fromcareful case-by-casemultidisciplinary evaluations.
INTRODUCTION
Breast cancer (BC) heterogeneity can be found at different
levels, from the classic histopathological characterization
to the more modern molecular classification. Indeed, BC
encompasses a collection of different diseases characterized
by different biological and pathological features, clinical
presentation, response to treatments, clinical behavior, and
outcome. Pathologists have been aware of the histological
diversity of breast carcinomas for a long time. According to the
World Health Organization (WHO) classification, BC can be
classified in up to 21 distinct histological types on the basis of
cell morphology, growth, and architecture patterns (Fig. 1) [1].
The most common histological type is invasive ductal breast
carcinoma of no special type (NST), which includes those
cancers without peculiar features tomerit classification in one
special type. BC special types, including the classic lobular
invasive carcinoma, represent25%ofall breastcancers [2].The
histopathological classification has a prognostic value [3].Two
extreme examples are the tubular carcinoma, associated with
an excellent prognosis, and metaplastic cancer, whose out-
come is generally unfavorable [4, 5].
Nowadays, tumor biology is the main determinant of
breast cancer treatment. On the basis of immunohistochem-
istry (IHC), BC consists of at least threemain groups: hormone
receptor (HR)-positive, human epidermal growth factor re-
ceptor 2 (HER2)-positive, and triple-negative disease (HR- and
HER2-negative).
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Endocrine manipulation is the cornerstone of therapy for
HR-positive tumors; anti-HER2 agents combined with chemo-
therapy or endocrine therapy are the standard treatment for
tumors overexpressing HER2. Chemotherapy represents the
only approach for the treatment of triple-negative breast
cancers, because no targeted therapy is available so far.
Morerecently,the furthersegmentationofBC into intrinsic
molecular subtypes based on different gene expression pro-
filing has allowed the identification of at least four different
subgroups with different prognosis and sensitivity to treat-
ment: luminal, normal-like, HER2-enriched, and basal-like [6].
HR-positive tumors mainly cluster within the luminal subtype,
which can be further divided into two entities: Luminal A and
Luminal B, with the lattermainly represented by HR1/HER21
or HR1 tumors with high Ki67 levels [7]. HER21/HR2 tumors
and triple-negative tumors mainly cluster within the HER2-
enriched and basal-like subgroups, respectively. Despite the
fact that BC classification based on routine pathologic
parameters such as HR, HER2, and Ki67 does not completely
recapitulate the gene expression profiling-based molecular
classification, it is nowadays applied in clinical practice as
a surrogate for the intrinsicmolecular subtypedefinition [8, 9].
However, this approach still presents some pitfalls. First,
intrinsic molecular subtypes were identified on the basis of
gene expression profiles. However, in recent years, we have
observed an exponential development of high-throughput
technologies and their application in cancer research. The
introduction of such techniques has indeed revealed deeper
levels of tumor heterogeneity. As an illustration, the in-
tegration of gene expression and gene copy number data
recently led to the identificationof at least10different clusters
of primary BC, with different prognoses [10]. Thus, molecular
classification as a field may be considered a work in progress.
Second, the main studies that led to the identification of
intrinsicmolecularsubtypeswerealmostcompletely limited to
ductal invasive breast cancers of no special type and did not
take uncommon histologies into account. Thus, molecular
classification is more a description of the heterogeneity of
invasive ductal carcinomas rather than an exhaustive repre-
sentation of the entire BC landscape. From this perspective,
a relevant study has been conducted by Weigelt et al. [11].
A panel of BC of special types (including invasive lobular,
mucinous, neuroendocrine, apocrine, invasive ductal with
osteoclastic giant cells, micropapillary, adenoid cystic, meta-
plastic, and medullary carcinoma) was analyzed by gene
expression profiling. The first relevant finding was that by
hierarchical analysis, some of the special types (like micro-
papillary carcinomas) constituted a distinct and separate
cluster of tumors, suggesting a high homogeneity at the
molecular level. Moreover, when classified according to the
intrinsic molecular classification, each BC special type (except
from apocrine carcinoma) fell in one molecular subtype only.
Figure 1. Histological special types of breast cancer. (A):Mucinous carcinoma. (B):Tubular carcinoma. (C):Adenoid cystic carcinoma. (D):
Cribriform carcinoma. (E): Medullary carcinoma. (F): Apocrine carcinoma. (G): Lobular pleomorphic carcinoma. (H): Micropapillary
carcinoma. (I):Metaplastic spindle cell carcinoma.
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On the other hand, within invasive ductal cancers of no special
type and classic invasive lobular cancers, all molecular
subtypes were represented, suggesting that each rare
histotype is more homogeneous at the transcriptome level
than more common entities. This was also confirmed at the
genomic level, with the demonstration of similar patterns of
gene copy number variations for samples of the same rare
histology [12]. In addition, some good-prognosis triple-
negative histotypes are classified as basal-like cancers based
on gene expression profiling, which is the intrinsic molecular
subtype with the worst prognosis [11]. As a consequence,
treatment decisions based on molecular features not taking
intoaccounthistological aspectsmayerroneously recommend
unnecessary aggressive therapies forgood-prognosis patients.
The main studies that led to the identification of
intrinsic molecular subtypes were almost completely
limited to ductal invasive breast cancers of no special
type and did not take uncommon histologies into
account. Thus, molecular classification is more a de-
scription of the heterogeneity of invasive ductal
carcinomas rather than an exhaustive representation
of the entire BC landscape.
In this review, we examine current knowledge about rare
BC histologies from a clinical point of view. In addition, when
applicable, evidence about specific genomic drivers of rare BC
entities will be also described.
CLINICOPATHOLOGICAL FEATURES OF RARE BC SUBTYPES
Good-Prognosis Group
Typically Hormone Receptor Positive
Puremucinous carcinoma is characterizedby theproductionof
abundant extracellular and/or intracellular mucin. The defini-
tion of pure mucinous carcinoma consists of nests of tumor
cells floating in lakes of mucin, whereas the mixed form also
contains common infiltrating ductal carcinomaNST [13–15]. A
precisely defined threshold in the percentage of mucinous
component for the distinction between pure and mixed
mucinous carcinoma is not well established. However, pure
mucinous carcinomas are generally defined as containing
more than 90% of mucin, and mixed mucinous carcinomas
are those containing 50%–90% of mucin [16]. The presence
of less than 50% of mucin identifies ductal carcinoma with
a mucinous component. Pure mucinous carcinoma accounts
for 1%–4%of all breast cancers, and it is generally diagnosed at
older ages. In a retrospective series of 11,400 cases of pure
mucinous carcinoma, themedianageatdiagnosiswas71years
versus 61 years observed in patients with infiltrative ductal
carcinomas [17].
Themost commonmammographic appearanceofpuremu-
cinous carcinoma is a low-densitymass lesionwithwell-defined
margins.On thesonographicexamination, these lesionspresent
isoechogenic echo texture relative to subcutaneous fat [18].
These lesions are mostly well-differentiated HR1 and
HER22. The axillary lymph nodes are rarely involved. These
features account for the favorable prognosis of this BC
subtype, with a 5-year BC-specific survival rate of 94%
compared with 82% of the infiltrating ductal carcinoma
counterpart. The overall more favorable outcome is main-
tainedover veryprolonged follow-up.The10-, 15-, and20-year
survival rates were 89%, 85%, and 81%, respectively, for pure
mucinous cases compared with 72%, 66%, and 62%, re-
spectively, for infiltratingductal carcinomacases [17]. Ina large
cohort including more than 1,200 cases, the 5-year overall
survival (OS) of patients with mucinous carcinoma was not
different fromtheOSof females fromtheage-matchedgeneral
population [19].
Tubular carcinoma accounts for less than 2% of invasive
breast cancers [20]. For the definition of pure tubular
carcinoma, at least 90% of the tumor should present tubular
architecture, composedof small roundoroval tubules of single
layer of epithelial cells that abut directly onto the adjacent
desmoplastic stroma. These lesions are usually detected by
screening mammography. The radiological appearance is a
small spiculated mass that mimics infiltrating ductal carci-
noma or radial scars [21].
Tubular carcinomas are nearly always hormone receptor-
positiveandwell-differentiated,with lowproliferation.HER2 is
generally neither overexpressed nor amplified [22]. When
compared with invasive carcinoma of no special type, tubular
carcinoma is more likely to be diagnosed at older age and be
smaller in size. Nodal involvement is reported in the range of
4%–17%. The prognosis of patients with tubular carcinoma is
very good. The largest series so far encompasses 444 patients
with tubular carcinoma [19]. The 5-year disease-free survival
(DFS) and OS were 94% and 88%, respectively, for tubular
carcinoma versus 80% and 77%, respectively, for carcinoma
“not otherwise specified”. More interestingly, the 5-year OS
was similar to age-matched female sets from the general
population.
Invasive cribriform carcinomas (ICCs) account for
0.1%–0.6% of breast cancers and are characterized by an
invasive component showing a predominantly cribriform
pattern [23]. The median age at diagnosis is 54–63 years [23,
24].These tumors are subdivided into pure andmixed. In pure
ICCs, the growth pattern is cribriform in more than 90% of
the lesion. ICCs with a cribriform pattern and a limited extent
of tubular invasive elements (less than 50%) are included
in pure subtype. Mixed ICCs also contain areas of less-well-
differentiated invasive carcinoma [25]. ICCs are generally
estrogen receptor-positive (ER1), low grade, and low pro-
liferating. Axillary lymph-nodal metastases are reported in
approximately 10% of the cases [26]. ICC has an excellent
prognosis in its pure form,whereasmore caution is needed for
the mixed variants.
Neuroendocrine carcinomas of the breast are defined by
the diffuse expression of neuroendocrine markers along with
the presence of morphologic neuroendocrine features. The
WHO classification describes three main histologic types:
neuroendocrine tumor, well-differentiated neuroendocrine
carcinoma, and poorly differentiated/small cell and invasive
breast carcinoma with neuroendocrine differentiation [2, 27].
The prevalence of the well-differentiated neuroendocrine
tumor is up to 0.5% of breast cancers [28]. With IHC,
synaptophysin or chromogranin must be expressed in .50%
of the cells. These tumors are generally low-grade ER1, and
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PgR1, and HER22, with favorable prognosis [29]. The high-
grade small-cell variant is described among the poor prog-
nostic group.
Typically Hormone Receptor Negative
Medullary carcinoma represents less than 2% of breast
carcinoma and occurs more frequently in younger women
[1]. It is composed of poorly differentiated cells, with large
vesicular nuclei and prominent nucleoli, arranged in syncytial
architecture with circumscribed margins. The distinctive
feature is a prominent lymphocytic infiltrate, both within the
tumor and at the periphery [30, 31]. These features must be
present in the entire tumor for the diagnosis of classical
medullary carcinoma. Cases that do not fulfill all these criteria
are definedas atypicalmedullary carcinomaor carcinomawith
medullary features.The mammographic appearance is a mass
with circumscribed margins; with sonography, medullary
carcinoma generally appears as homogeneous or inhomoge-
neous hypoechoic mass with well-defined margins [32].
Magnetic resonance appearance is often indicative of a benign
lesion [33].
Most of medullary cancer presents with triple-negative
assets at immunohistochemistry, with cytokeratin 5/6 posi-
tivity [34, 35]. The majority of medullary carcinomas are
aneuploid and highly proliferative. Despite these unfavorable
histologic features, the prognosis of patients with medullary
carcinoma is generally good. The medullary histotype is more
common in the case of BRCA1mutations. According to a study
includingmore than3,600 cases fromtheBreast Cancer Family
Registry consortium, the prevalence of medullary histotype
in BRCA1-associated tumors exceeds 16% [36].
The incidence of nodal involvement is lower than other
carcinomasof thebreast. Inacaseseries including46cases,the
10-year-distant relapse-free survival reached 95% [34].
Adenoid cystic carcinoma of the breast is very rare,
accounting for less than 1% of breast cancers. Adenoid cystic
carcinoma predominantly affects postmenopausal women,
with a median age at diagnosis of 60 years [37]. Morpholog-
ically, these tumors are similar to adenoid cystic carcinomas
arising in the salivary glands, showing epithelial cells and
myoepithelial cells arranged in tubular and cribriform ar-
chitecture. The mitotic activity is generally low.
Mammographically, adenoid cystic carcinoma presents as
either irregular masses or growing asymmetric densities, with
minimal vascularity on color Doppler imaging [38]. Lymph-
nodal involvement is reported in 0%–8% of the cases in the
largest published series [39]. With IHC, these tumors are
generally HR2 and HER22 [40]. The prognosis is generally
good, with 10-year OS exceeding 90% [41, 42]. Metastases
are rare and generally spread many years after diagnosis,
independently from axillary nodal involvement at initial
diagnosis.The lung is one of the most frequent sites of distant
recurrence. However, even in the presence of local or distant
recurrence, patients have a prolonged and indolent clinical
course [37].
This extremely rare tumor is one of the salivary gland-like
tumors of the breast. At imaging, it appears as a well-
circumscribed mass.This tumor generally lacks the expression
of hormone receptors and HER2. A positive stain for epithelial
membrane antigen and S100 protein is frequently reported
[43]. This tumor is generally described as having a good
prognosis. However, a note of caution is required, taking into
account the paucity of available data.
Also known as juvenile carcinoma, secretory breast
carcinoma is extremely rare, representing 0.1%–0.2% of all
breast cancers. It accounts for most of the breast cancers
diagnosed in childhood.Thedistinctivepathological character-
istics are intracellular or extracellular secretion and granular
eosinophilic material [44]. The median age at diagnosis is
25–40 years [45, 46]. The ultrasonography (US) appearance
generally resembles a benign lesion [47].
Secretory breast cancers are usually ER-, PgR-, and HER2-
negativeandhave lowKi67expression.These tumorsgenerally
harbor the t(12;15)ETV6-NTRK3 translocation [48]. The ETV-
NTRK fusion results in the expression of a functional tyrosine
kinaseswithpotent transformingactivity. Secretory carcinoma
is associated with a good prognosis. Few metastatic cases are
described; recurrences generally occurred after very pro-
longed disease-free intervals (12–20 years) [49].
Intermediate Prognosis
Apocrine Carcinoma
The apocrine epithelium is a normal constituent of apocrine
glands, consisting of cells with eosinophilic cytoplasm and
a large nucleus located near the base of the cell [50]. Apocrine
phenotype is observed in a spectrum of breast epithelial
lesions, ranging from benign metaplasia to apocrine carci-
noma. The incidence of apocrine carcinoma is reported in the
range of 0.3%–4% of all cases, mostly because of the lack of
uniform criteria for its diagnosis. The more stringent defini-
tion considers as apocrine carcinoma only those neoplasms
composed entirely or predominantly of apocrine-type epithe-
lium [51]. Pure apocrine carcinomas are generally ER2 and
progesteron receptor (PgR)2, and androgen receptor (AR)
positive [52]. HER2 is overexpressed in up to 54% of the cases
[53]. Mammographic presentation do not differ from that
of ductal carcinoma. Conflicting data are available on the
outcome of invasive apocrine carcinoma. Some studies report
that the prognosis of apocrine carcinoma is the same with
other types of breast carcinoma, with the outcome depending
on grade, HER2, and hormone receptor expression. A recently
published retrospective analysis has includedmore than 6,800
cases of infiltrating ductal carcinoma NST and 72 cases of
apocrine carcinoma. In this study, apocrine carcinomas were
subdivided inpureapocrine carcinoma (ER2, PgR2, AR1) and
apocrine-like carcinoma (ERorPgR1, AR2) [54].Thediagnosis
of pure apocrine carcinoma was independently correlated
with a worse DFS, whereas infiltrating ductal carcinoma and
apocrine-like BC showed similar outcomes. However, when
considering only triple-negative breast cancers, the prognosis
of the apocrine histotype was intermediate between the
histotypes with the best outcome (like medullary carcinomas)
and the ones determining theworst outcome (likemetaplastic
carcinomas) [55].
Poor-Prognosis Group
Pleomorphic Lobular Carcinoma
Pleomorphic lobular carcinoma is a very rare and aggressive
variant of lobular carcinoma, accounting for ,1% of all BCs
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[56, 57]. Pleomorphic lobular carcinoma is characterized by
a diffuse spreading pattern arranged in single lines similar to
classic invasive lobular cancer. However, the pleomorphic
variant is composed of cells with more evident nuclear atypia
and pleomorphism [58].
Pleomorphic lobular carcinoma generally affects post-
menopausal women [59]. Similarly to the classic variant,
pleomorphic lobular carcinoma generally presents with
hormone receptor expression and negative staining for E-
cadherin. These tumors, however, show a more aggressive
nature, evidenced by higher-grade cytological features, the
presence of lymphovascular invasion, and a more ad-
vanced stage at presentation. HER2 is overexpressed in up
to 30% of the cases. Pleomorphic lobular cancer shares the
same radiological challenges of the classic lobular counterpart
[60]. The more aggressive biological features account for the
overall poorer prognosis as compared with classic lobular
carcinoma, being the outcome of pleomorphic lobular cancer
patients similar to high-grade, invasive ductal carcinoma
patients [51].
Invasive Micropapillary Carcinoma
Invasive micropapillary carcinoma is characterized by exten-
sive lymphatic vessel invasion [1, 61].This feature accounts for
the high propensity for nodal metastases, reported in up to
70% of the cases, as well as for the high incidence of early
recurrences in skin and in the chestwall [62, 63].Median ageat
diagnosis is 52.5 years. With mammography, invasive micro-
papillary carcinoma appears as high-density mass, generally
with spiculatedmargins [64].The expression of HR is reported
in approximately two-thirds of the cases. A positive HER2
status is described in up to 50% of the cases. This subtype is
associatedwith a poor prognosis. In a study including 98 cases
of invasive micropapillary carcinoma, the 10-year OS was 48%
[65].
Metaplastic Carcinoma
Metaplastic breast cancers are a heterogeneous group of
tumors characterized by differentiation of the neoplastic
epithelium into squamous or mesenchymal phenotype. Re-
cently the WHO Working Group proposed this descriptive
classification including squamous cell carcinoma, spindle cell
carcinoma, metaplastic carcinoma with mesenchymal differ-
entiation, and mixed metaplastic carcinoma. The metaplastic
carcinoma group also includes low grade adenosquamous
carcinomas and fibromatosis-like metaplastic carcinomas
that are associated with more favorable prognosis [1]. The
incidence of metaplastic breast carcinoma is in the range of
0.2%–0.6%, and themedian age at presentation is 47–61 years
[66–68].
A relatively high proportion of metaplastic carcinomas are
diagnosed in Hispanic or black women [1, 4].With mammog-
raphy, metaplastic carcinoma usually appears as a round,
lobular, oval lesion with a predominantly circumscribed, high-
density mass. On US, metaplastic carcinoma may presents as
having solid and cystic components and may be micro-
lobulated [31, 69].
These tumors are generally poorly differentiated and ER-,
PgR-, and HER2-negative, with high Ki67 and p53 positivity [4,
39].Themajority ofmetaplastic carcinomas arenode-negative
but have a high potential for metastatic spread [4]. Up to 10%
of the patients present with de novo metastatic disease, and
local or distant relapse is reported in.50% of the cases [70].
The prognosis is poorer than that of triple-negative invasive
ductal carcinoma [67]. In the study by Hennessy et al. [71]
including exclusively the squamous-cell subtype, the median
OS was 37 months. From the onset of distant metastasis,
survival is generally less than 1 year [5, 72]. On the other hand,
well-differentiated metaplastic carcinomas, which are ex-
tremely rare, are generally associated with a good prognosis.
High-Grade Small Cell Neuroendocrine Carcinoma
This subtype is similar to neuroendocrine tumors arising in the
lung. The diagnosis requires the exclusion of a nonmammary
primary. Similar to other neuroendocrine tumors, neuroen-
docrinemarkersmust be expressed in at least 50%of the cells.
The positivity of ER and PgR inversely correlates with the
degreeofdifferentiation. HER2 is typically negative [73].These
tumors are generally associated with an aggressive disease
course.
GENOMIC FEATURES OF RARE BC HISTOLOGIES
The comprehensive evaluation of the genomic landscape
of BC is one of the main goals of the current research. Only
a few studies have focused on rare BC entities so far. The
observation that rareBChistologies aremorehomogeneousat
the transcriptome level than classic histologies suggests that
a similar degree of homogeneity may be also found at the
genomic level, thus representingamodel to investigate cancer
pathways (Fig. 2).Hereinwesummarize themost relevantdata
about genomic characterization of rare BC histologies.
Good-Prognosis Group
A recentworkevaluated the genomic profiles of 59BC samples
of 10 special types [12]. The first relevant result was that
samples of the same histology presented similar degrees of
gene copy number variations. In addition to that, some of
the special types with the best prognosis (adenoid cystic,
mucinous, and tubular carcinomas with neuroendocrine
features) presented the lowest levels of gene copy number
changes. Similarly, typically low-grade BC special types such as
adenoid cystic, mucinous, and carcinomas presented low
levels ofgenomic instability and simplexgenomic architectural
patterns.
In regard to specific aberrations selectively present or
absent in rare good-prognosis histologies, some examples can
be proposed. Mucinous, neuroendocrine, and adenoid cystic
BC special types lack 1q gains and 16q losses, which are
hallmark features of low-grade invasive ductal carcinomas,
thus suggesting that pathways driving the carcinogenesis of
these rareentitiesmaybeunique [12, 74,75]. In support of this
hypothesis, mucinous carcinomas of the breast lack PIK3CA
and AKT1 mutations, which is in contrast with the high
frequency (up to 45%) at which PIK3CA mutations occur in
luminal BCs [76] (TCGA). Within the typically hormone
receptor-negative good-prognosis BC special types, we can
identify two main histologies for which specific fusion genes
have been identified. Adenoid cystic BCs recurrently harbor
the t(6;9)(q22–23;p23–24) translocation that leads to the
formation of the MYB-NFIB fusion gene, which involves the
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MYB oncogene and the NFIB transcription factor. Indeed,
a recentwork reported the presence of this translocation in 12
of 13 analyzed adenoid cystic breast cancers. Interestingly, all
13 adenoid cystic BCs displayed significantly higher MYB
expression levels than grade-matched and basal-like ductal
carcinomas [74]. The t(12;15)ETV6-NTRK3 translocation,
which is pathognomonic for secretory carcinoma, has already
been described [48].
Finally, despite the fact that medullary BCs seem to share
main genomic features with basal-like BCs, such as 1q and 8q
gains and X losses and TP53 mutations, some genomic
aberrations seem to occur more frequently in medullary BC,
like cytokeratin 5/6 expression; 10p, 9p, and 16q gains; 4p
losses; and 1q, 8p, 10p, and 12p amplicons [35].
Poor-Prognosis Group
The interest in deciphering specific pathways of progressionof
rare aggressive BC subtypes relies on the possible identifica-
tion of driver aberrations that may be also involved in the
progression of commonhistologies. From this perspective, the
results of whole exome sequencing of lobular pleomorphic,
micropapillary, and metaplastic BCs have been recently
presented [77]. The most interesting result was represented
bymutations in a gene that had not been previously described
as a cancer-related gene, PYGM, in up to 30% of pleomorphic
lobular cancers. This gene encodes for the muscle isoform of
glycogen phosphorylase and was shown to be constantly
underexpressed in BC (irrespectively of the histological or
molecular subtype) comparedwith normal breast tissue in the
TCGA database. Similar results were also obtained when
looking at PYGM expression in other cancers, thus suggesting
that glycogen metabolism might represent a pathway for
cancer progression. TP53 and PIK3CA were extremely fre-
quently mutated in metaplastic BCs (78% and 48%, re-
spectively). The phosphatidylinositol 3-kinase (PI3K)/Akt
pathway is frequently aberrant in basal-like breast cancers,
but PIK3CA mutations generally occur at a low rate (,10%)
[78], which contrasts with what has been observed for
metaplastic BCs, indicating a potential rationale to test new
selectivePIK3CA inhibitors in this entity. Finally,micropapillary
BCs showed the typical mutation spectrum of luminal B BCs,
with the most frequently mutated genes being PIK3CA, TP53,
MAP2K4, andGATA3. A recently publishedwork that explored
genomic features of micropapillary BC also found that this
entity does not seem to extensively differ from other luminal
cancers and failed to demonstrate pathognomonic genomic
features that drive micropapillary BCs [79].
RARE HISTOLOGIES: IMPLICATIONS FOR LOCAL AND
SYSTEMIC THERAPY
Special histologies often present peculiar clinical behaviors.
However, the fact that these entities can be very rare has
impaired their extensive clinical evaluation. Indeed, the
majority of information on outcome and treatments derives
from small series and case reports. As a consequence, clear
recommendations about clinical management of BC special
histologies are still lacking.
The recommendations for locoregional treatments follow
those of BCs of no special type. Indeed, in a study including
mucinous, medullary, tubular, and invasive ductal BC, a similar
rate of local failure after breast conserving therapy was
observed [80]. The only exception is secretory carcinoma.
Because it usually arises in childhood, breast-conserving
surgery represents an issue because it would be preferable
to avoid radiotherapy. In the past years, the role of axillary
dissection has been questioned for the good-prognosis rare
histotypes. However, because the sentinel node biopsy is
nowadays a standard procedure with negligible side effects,
themanagement of axillary lymph nodes is no longer an issue.
The adjuvant systemic therapy is more critical. The 2014
NCCN Guidelines [81] include specific treatment recommen-
dations for the favorable tubular and mucinous histotypes. In
case of HR positivity and in the absence of nodal involvement,
adjuvant endocrine therapy can be avoided in case of tumor
size (T),1cm, shouldbeconsidered for Tbetween1and3cm,
and is recommended for T $ 3 cm. In case of nodal
involvement, endocrine therapy with or without chemother-
apy is indicated. In the case of negative expression of HR, ER,
and PgR status should be reassessed. If HR2 is confirmed,
Figure 2. Heterogeneity of breast cancer: histotypes, molecular classification, and immunohistochemical classification.
Abbreviations: ER, estrogen receptor; HER2, human epidermal growth factor receptor 2.
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patients shouldbe treatedashaving theusualBChistology.The
metaplastic cancer shares the same indications of ductal
histology. The 2013 St. Gallen consensus conference simply
recommends endocrine therapy for endocrine-responsive
“special histological types” (cribriform, tubular, andmucinous)
and cytotoxic therapy for endocrine nonresponsive special
types (apocrine, medullary, adenoid cystic, and metaplastic)
[9]. It is reported that adenoid cystic carcinoma may not
require adjuvant chemotherapy, in case of node negativity. As
previously discussed, the rarity of these tumors impedes the
buildup of a robust scientific evidence. Thus, it is assumed by
current international guidelines that the same chemotherapy
regimens used for common BC histotypes should also be
proposed in case of uncommon histologies, when indicated.
Such an indication, however, reflects the lack of prognostic
data and does not necessarily recapitulate the intrinsic
biological chemosensitivity of different BC histotypes. As
reported in this review,most of the good-prognosis endocrine-
sensitive rare histotypes usually belong to the Luminal
A subtype, which tends to be chemoresistant. Indeed, in
a retrospective study of more than 500 BC patients treated
with conventional neoadjuvant chemotherapy, the clinico-
pathological response of BC of special type was significantly
poorer. However, despite a low rate of response, the prognosis
of mucinous and apocrine BC was good [82]. Therefore, the
indication to administer potential toxic chemotherapy for rare
BCswith very good prognosis should be carefully evaluated by
balancing potential benefits and disadvantages. From this
perspective, anthracycline-free schedules could represent an
option. In regard to more aggressive rare BC histotypes, no
data on specific chemotherapy regimens are available; thus,
the same agents used for common BCs should be proposed.
However, metaplastic BC deserves specific considerations.
Small retrospective studies in the neoadjuvant andmetastatic
setting have shown that this heterogeneous BC entity is
chemoresistant to conventional chemotherapy. In a small
retrospective studybyChenetal. [83], only 18%ofmetaplastic
BC patients showed a partial response to neoadjuvant
chemotherapy, and only 8% of the patients responded to
first-line chemotherapy in themetastatic setting. In this series,
no patient responded to anthracycline-, vinorelbine-, or
cyclophosphamide-based regimens. Similarly, theM.D.Ander-
son Cancer Center experience reported only a 10% complete
response rate in patients with metaplastic BC undergoing
neoadjuvant chemotherapy [84]. Some scattered evidence
suggests that metaplastic breast cancer might benefit from
chemotherapy tailored on the specific metaplastic differenti-
ation of cancer cells. This assumption derives from the
observation that the clinical behavior of metaplastic breast
cancer seems to reflect the behavior of sarcomas (in case of
spindle cell metaplastic breast cancer) or squamous cell
carcinomas (in case of epidermoid metaplastic breast cancer).
Indeed, sarcomatoid metaplastic BC patients often develop
pulmonary metastasis, and squamous cell metaplastic BC is
commonly associated with local relapses even after local
radiotherapy. Sporadic responses to ifosfamide- and
anthracycline-based chemotherapy and to platinum-based
chemotherapy have been reported for sarcomatoid and
epidermoid metaplastic BC, respectively [40, 71, 85].
Considering the recent results fromprospective trials support-
ing the role of platinum salts for patients with triple-negative
breast cancers, there is the rationale to consider the in-
corporationofsuchdrugs in the treatmentofearlyoradvanced
epidermoid metaplastic breast cancer.
It is assumed by current international guidelines that
the same chemotherapy regimens used for common
BC histotypes should also be proposed in case of
uncommon histologies, when indicated. Such an
indication, however, reflects the lack of prognostic
data and does not necessarily recapitulate the
intrinsic biological chemosensitivity of different BC
histotypes.
From a biological perspective, the observation that meta-
plastic cancersmay be enriched in cells with stem-like features
may account for their resistance to therapy and metastatic
potential [86]. On the basis of recent translational studies,
there may be the rationale to test selective PI3K inhibitors for
this particular BC subset.Moreover, some preclinical evidence
also suggests that epidermal growth factor receptor may
potentially represent a target for squamous cell metaplastic
breast cancers [87].
CONCLUSION
The management of rare breast cancer histotypes represents
a real challenge in daily clinical practice. Indeed, these entities
are rare, and conducting prospective studies focused on rare
breast cancers is unrealistic. Moreover, rare breast cancers
represent distinct entities with different clinical behavior and
response to treatment, suggesting that they might also be
driven by few genomic specific events. From a biological
perspective, rare BC histologies may represent discrete
homogeneous molecular entities, suggesting that they might
be also driven by few genomic specific events. Therefore, in-
depth genomic evaluation of aggressive rare histologiesmight
allow the identification of specific cancer pathways that may
also be involved in the progression of more common
histologies. A more comprehensive study of the clinical and
genomic aspects of rare histological subtypes is needed to
provide a more complete landscape of BC disease to support
a more personalized treatment decision.
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